Department of Clinical Oncology, Queen Elizabeth Hospital, Room 1305, 13/F, Block R, 30 Gascoigne Road, Kowloon, Hong Kong.
Expert Rev Mol Diagn. 2011 Sep;11(7):691-4. doi: 10.1586/erm.11.57.
MicroRNAs regulate target gene expression through translation repression or mRNA decay, and they are emerging as important modulators in cellular pathways. Previous studies have shown the occurrence of epigenetically modified miRNAs in colorectal cancer (CRC), identifying these miRNA methylation signatures may provide candidate markers for the detection of malignant colonocytes. Fecal-based tests are widely adopted as noninvasive methods for CRC diagnosis, thus several studies have attempted to use miRNAs from feces as CRC markers. This article evaluates a recently published study investigating the usefulness of epigenetically silenced miRNAs in fecal specimens, including miR-34b/c and miR-148a, as potential markers for CRC screening and prognosis.
MicroRNAs 通过翻译抑制或 mRNA 降解来调节靶基因表达,它们作为细胞通路中的重要调节剂而出现。先前的研究表明,在结直肠癌 (CRC) 中存在表观遗传修饰的 miRNAs,鉴定这些 miRNA 甲基化特征可能为恶性结肠细胞的检测提供候选标志物。基于粪便的检测被广泛采用作为 CRC 诊断的非侵入性方法,因此有几项研究试图使用粪便中的 miRNAs 作为 CRC 标志物。本文评估了一项最近发表的研究,该研究调查了粪便中表观遗传沉默的 miRNAs(包括 miR-34b/c 和 miR-148a)作为 CRC 筛查和预后潜在标志物的有用性。